Reversal Treatment and Clinical Outcomes in Acute Intracranial Haemorrhage Associated with Oral Anticoagulant Use: Protocol of a Planned Systematic Review and Meta-analysis

Overview

Journal BMJ Open

Specialty General Medicine

Date 2025 Feb 18

PMID 39965957

Authors

Mattias Tallroth

Linda Ostlundh

Andras Buki

Yang Cao

Mia von Euler

Jakob O Strom

Affiliations

Soon will be listed here.

Abstract

Introduction: Reversal treatment is commonly used for managing oral anticoagulant (OAC)-associated intracranial haemorrhages. Its effects on mortality are still understudied, particularly in various subtypes of intracranial haemorrhages. This systematic review and meta-analysis aims to synthesise the available data to study the impact of reversal therapies on mortality following various OAC-associated acute intracranial haemorrhages.

Methods And Analysis: This protocol follows the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) Protocols, and the final review will be reported in accordance with the PRISMA reporting guidelines. This systematic review and meta-analysis will include studies that assess contemporary reversal treatment in comparison to no reversal treatment, in cases of OAC-associated intracranial haemorrhage. Stratification will be performed for the types of bleeding as well as OAC at bleeding onset. Preliminary searches to determine search term inclusions were conducted in May-August 2024 in the electronic databases Embase, PubMed, Scopus and Web of Science without language and publication date restrictions. Randomised controlled studies, non-randomised controlled trials, and observational studies will be considered for the final meta-analysis. Three reviewers (MT, JOS and AB) will screen titles and abstracts, and one reviewer (MT) will subsequently conduct full-text screening.Risks of bias will be assessed by MT using tools such as Risk of Bias 2, Risk Of Bias In Non-randomised Studies - of Interventions and the Newcastle-Ottawa Scale. Heterogeneity among the study results will be assessed using the I² statistic. If appropriate, a random-effects meta-analysis model will be performed. Subgroup analyses and meta-regression (if applicable) will be performed to assess sources of heterogeneity among (1) intracranial haemorrhage types, (2) OAC drugs and (3) study types, with randomised controlled trials being the primary focus.

Ethics And Dissemination: Ethical approval is not needed as this project involves previously published data. We intend to publish the results in a peer-reviewed journal.

Prospero Registration Number: CRD42024556420.

References

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

Powell K, Curtiss 3rd W, Sadek E, Hecht J . Is reversal of anticoagulants necessary in neurologically intact traumatic intracranial hemorrhage?. Pharmacotherapy. 2023; 44(3):241-248. DOI: 10.1002/phar.2901. View

Greenberg S, Ziai W, Cordonnier C, Dowlatshahi D, Francis B, Goldstein J . 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2022; 53(7):e282-e361. DOI: 10.1161/STR.0000000000000407. View

Huttner H, Gerner S, Kuramatsu J, Connolly S, Beyer-Westendorf J, Demchuk A . Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor-Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care. Stroke. 2021; 53(2):532-543. DOI: 10.1161/STROKEAHA.121.034572. View

Steiner T, Weitz J, Veltkamp R . Anticoagulant-Associated Intracranial Hemorrhage in the Era of Reversal Agents. Stroke. 2017; 48(5):1432-1437. DOI: 10.1161/STROKEAHA.116.013343. View

Boulouis G, Morotti A, Pasi M, Goldstein J, Gurol M, Charidimou A . Outcome of intracerebral haemorrhage related to non-vitamin K antagonists oral anticoagulants versus vitamin K antagonists: a comprehensive systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2017; 89(3):263-270. DOI: 10.1136/jnnp-2017-316631. View

Chaudhary R, Singh A, Chaudhary R, Bashline M, Houghton D, Rabinstein A . Evaluation of Direct Oral Anticoagulant Reversal Agents in Intracranial Hemorrhage: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022; 5(11):e2240145. PMC: 9636520. DOI: 10.1001/jamanetworkopen.2022.40145. View

Frol S, Sagris D, Sabovic M, Ntaios G, Oblak J . Dabigatran Reversal With Idarucizumab and In-Hospital Mortality in Intracranial Hemorrhage: A Systematic Review of Real-Life Data From Case Reports and Case Series. Front Neurol. 2021; 12:727403. PMC: 8653877. DOI: 10.3389/fneur.2021.727403. View

Connolly S, Crowther M, Eikelboom J, Gibson C, Curnutte J, Lawrence J . Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2019; 380(14):1326-1335. PMC: 6699827. DOI: 10.1056/NEJMoa1814051. View

10.

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M . Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015; 4:1. PMC: 4320440. DOI: 10.1186/2046-4053-4-1. View

11.

Milling T, Pollack C . A review of guidelines on anticoagulation reversal across different clinical scenarios - Is there a general consensus?. Am J Emerg Med. 2020; 38(9):1890-1903. PMC: 9245126. DOI: 10.1016/j.ajem.2020.05.086. View

12.

Ip B, Pan S, Yuan Z, Hung T, Ko H, Leng X . Prothrombin Complex Concentrate vs Conservative Management in ICH Associated With Direct Oral Anticoagulants. JAMA Netw Open. 2024; 7(2):e2354916. PMC: 10848059. DOI: 10.1001/jamanetworkopen.2023.54916. View

13.

Haupenthal D, Schwab S, Kuramatsu J . Hematoma expansion in intracerebral hemorrhage - the right target?. Neurol Res Pract. 2023; 5(1):36. PMC: 10373350. DOI: 10.1186/s42466-023-00256-6. View

14.

Pan R, Cheng J, Lai K, Huang Q, Wu H, Tang Y . Efficacy and safety of prothrombin complex concentrate for vitamin K antagonist-associated intracranial hemorrhage: a systematic review and meta-analysis. Neurol Sci. 2019; 40(4):813-827. DOI: 10.1007/s10072-019-3726-x. View

15.

Desmettre T, Dehours E, Samama C, Jhundoo S, Pujeau F, Guillaudin C . Reversal of Vitamin K Antagonist (VKA) effect in patients with severe bleeding: a French multicenter observational study (Optiplex) assessing the use of Prothrombin Complex Concentrate (PCC) in current clinical practice. Crit Care. 2012; 16(5):R185. PMC: 3682287. DOI: 10.1186/cc11669. View

16.

Pollack Jr C, Reilly P, van Ryn J, Eikelboom J, Glund S, Bernstein R . Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N Engl J Med. 2017; 377(5):431-441. DOI: 10.1056/NEJMoa1707278. View

17.

Gerner S, Kuramatsu J, Sembill J, Sprugel M, Endres M, Haeusler K . Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage. Ann Neurol. 2018; 83(1):186-196. DOI: 10.1002/ana.25134. View

18.

Steiner T, Poli S, Griebe M, Husing J, Hajda J, Freiberger A . Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol. 2016; 15(6):566-73. DOI: 10.1016/S1474-4422(16)00110-1. View

19.

Dewidar O, Lotfi T, Langendam M, Parmelli E, Saz Parkinson Z, Solo K . Good or best practice statements: proposal for the operationalisation and implementation of GRADE guidance. BMJ Evid Based Med. 2022; 28(3):189-196. PMC: 10313969. DOI: 10.1136/bmjebm-2022-111962. View

20.

Katsanos A, Schellinger P, Kohrmann M, Filippatou A, Gurol M, Caso V . Fatal oral anticoagulant-related intracranial hemorrhage: a systematic review and meta-analysis. Eur J Neurol. 2018; 25(10):1299-1302. DOI: 10.1111/ene.13742. View